Date presented at the 2013 Conference of The American Society of Breast Surgeons (ASBrS) shows promising results for non-surgical cryoablation treatment of breast cancer. The results were presented by Eisuke Fukuma, M.D., Ph.D., Chairman and Director of Breast Center, Director of Breast Disease Kameda Medical Center in Kamogawa City, Chiba, Japan.

Cryoablation, also be called percutaneous ablation,…

Changes in estrogen breakdown, or metabolism, may be one of the mechanisms by which aerobic exercise lowers a woman’s breast cancer risk. A study discussing data that suggests that exercise influences estrogen metabolism was published earlier today in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Exercise boosts the immune system and helps keep a persons weight in…

Men who reported sleep disorders or ongoing sleeping problems, including difficulty falling asleep and staying asleep, had up to a twofold increased risk for prostate cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Sleep can often be a barometer of your overall health for both men and women. In many cases, people in good health…

Data presented at the 2013 annual meeting of the American Association for Cancer Research (AACR) held in Washington, D.C., April 6-10, 2013, shows the effect of increased physical activity on estrogen levels in postmenopausal women. The data generated new insights into the ways in which physical activity affects how much estrogen is broken down and secreted in the urine. These findings enhance understanding of the potential biological…

Data presented at the 2013 annual meeting of the American Association for Cancer Research (AACR) held in Washington, D.C., April 6-10, 2013, shows the effect of increased physical activity on estrogen levels in postmenopausal women. The data generated new insights into the ways in which physical activity affects how much estrogen is broken down and secreted in the urine. These findings enhance understanding of the potential biological…

Results from a large Dutch study shows that women with breast cancer who had a BRCA1 mutation had significantly worse overall and recurrence-free survival rates compared with patients without BRCA mutations, but no evidence for a difference in survival was found between patients with BRCA2 mutations and those without a BRCA mutation. The data was presented during the Annual Meeting of the American Association for Cancer Research (AACR)…

In breast cancer screening mammography has been proven to one of the most effective detection mechanisms available. Today, it is considered the only screening options that reduces mortality. However, while mammography is still the gold standard of breast cancer screening, reports show that there is increasing awareness of subpopulations of women for whom mammography has reduced sensitivity. Furthermore, over the last decade, mammography has created much debate because of observed false…

After the initial publication of Nutrition and Physical Activity Guidelines for Cancer survivors by the American Cancer Society (ACS) in 2006 with a follow-up in 2012, researchers started to explore the potential benefits of lifestyle choices among cancer survivors. The unifying message, based on these guidelines, is that lifestyle, including diet, has a major influence on cancer survivors and is considered as essential for cancer prevention.

Now a new study by…

On February 22^nd, 2013, the U.S. Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (T-DM1; Kadcyla™, Genentech), as a single medicine, for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with trastuzumab (Herceptin®, Genentech) and a taxane chemotherapy. The newly approved drug is the…

Market analysts at Millennium Research Group say that the growing demographic at risk for breast cancer and increasing compliance with screening programs will spur demand for breast biopsies. Additionally, patients and clinicians are showing a growing preference for minimally invasive biopsies over open surgical alternatives. As a result, sales of breast biopsy devices used in these procedures will expand at a steady pace through…

A team of researchers led by Goutham Narla, MD, PhD, at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, and collaborators at the Mount Sinai School of Medicine and Erasmus Medical Center, have discovered a gene variant that drives the spread of breast cancer.

The results of the study are published in…

Patients who received one year of bevacizumab (Avastin®, Genentech/Roche), an angiogenesis inhibitor that slows the growth of new blood vessels in addition to chemotherapy for the postsurgical treatment of triple-negative breast cancer, had no statistically significant improvement in invasive disease-free survival compared with patients treated with…

Ten-year follow-up results from the U.K. Standardization of Breast Radiotherapy Trials (START), presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas, December 4-8, shows that appropriately dosed hypofractionated radiotherapy was gentle on healthy tissues and effective in controlling local-regional early breast cancer.

“Long-term follow-up confirms that a lower total dose of radiation in fewer, slightly larger fractions delivered over…

In estrogen receptor (ER)-positive early breast cancer, 5 years of tamoxifen greatly reduces recurrence throughout the first decade (years 0-9) with little further gain later. ER+ treatment also reduces breast cancer mortality (BCM) substantially throughout years 0-14. Now, ongoing research from the international ATLAS (Adjuvant Tamoxifen — Longer Against Shorter) study has shown that ten years of adjuvant treatment with tamoxifen provided women with estrogen…

For the first time, researchers have conducted a large trial in which they tested the entire genome of individual breast cancers to help personalize treatment. They released their findings at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna (September 28 - October 2, 2012). 

In recent years, a number of drugs have been developed that target specific genetic alterations in cancer. To choose which of these drugs are suitable for individual patients,…

Two new studies presented at ESMO 2012, the meeting of the European Society for Medical Oncology in Vienna, Austria (September 28 - October 2, 2012) show how improvements in breast cancer treatments are making it possible for more women to conserve their breasts following therapy. However, the trials but raise concerns about whether enough women are being offered these approaches.…

Results of a large prospective study on the treatment of early breast cancer presented during the 2012 Breast Cancer Symposium at the San Francisco Marriott Marquis in San Francisco, CA, September 13-15, 2012, determined that the use of a novel device called MarginProbe helps ensure that sufficient tissue is removed during a lumpectomy.  This results in fewer additional surgeries helping to avoid cost of having to remove larger amounts of tissue. For patients, this could…

The National Breast Cancer Foundation, Inc.® (NBCF) earlier today announced the official launch of its Early Detection Plan (EDP), a new free iPhone app designed to encourage women to become more proactive about their health by scheduling reminders via push notifications to perform routine breast self-exams and schedule clinical…

Stress can promote breast cancer cell colonization of bones, Vanderbilt Center for Bone Biology investigators have discovered. The preclinical studies, reported on July 17 in PLoS Biology, demonstrate that activation of the sympathetic nervous system, which is active in response to stress, primes the bone environment for breast cancer cell metastasis.

In addition, the…

Results from the phase III CLEOPATRA study showed that women with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of pertuzumab (Perjeta™, Genentech/Roche), trastuzumab (Herceptin®, Genentech/Roche) and docetaxel chemotherapy, compared to trastuzumab and docetaxel chemotherapy alone. in the Phase III . These data will be submitted for presentation at an upcoming medical meeting.…